

12-5-03

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/660,256
		Filing Date	September 11, 2003
		First Named Inventor	Arthur Ramazanov
		Art Unit	
		Examiner Name	
Total Number of Pages in This Submission (including this transmittal form)	11	Attorney Docket Number	04287/100M315-US1

ENCLOSURES (Check all that apply)				
<input checked="" type="checkbox"/> Fee Transmittal Form (1 page) <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Certificate of Express Mailing (1 page)		
<table border="1"><tr><td>Remarks</td><td>The Information Disclosure Statement includes an Information Disclosure Statement (4 pages), Form PTO SB/08 (4 pages) and 54 documents</td></tr></table>			Remarks	The Information Disclosure Statement includes an Information Disclosure Statement (4 pages), Form PTO SB/08 (4 pages) and 54 documents
Remarks	The Information Disclosure Statement includes an Information Disclosure Statement (4 pages), Form PTO SB/08 (4 pages) and 54 documents			

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	DARBY & DARBY P.C. S. Peter Ludwig - 25,351
Signature	
Date	December 2, 2003

Express Mail Label No.	Dated: _____
------------------------	--------------

{W:\04287\100M315-US1\00093417.DOC *04287100M315-US1* }



Application No. (if known): 10/660,256

Attorney Docket No.: 04287/100M315-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

EL982106141-US

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 2, 2003


Date

Signature


Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal form (1 page)
Fee Transmittal for FY 2004 (1 page)
Information Disclosure Statement (4 pages)
Form PTO SB/08 (4 pages)
54 documents
Return receipt postcard



FEE TRANSMITTAL for FY 2004 <small>Effective 10/01/2003, Patent fees are subject to annual revision.</small>		Complete if Known																																												
		Application Number	10/660,256																																											
		Filing Date	September 11, 2003																																											
		First Named Inventor	Arthur Ramazanov																																											
		Examiner Name																																												
		Art Unit																																												
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Attorney Docket No.	04287/100M315-US1																																											
TOTAL AMOUNT OF PAYMENT (\$)		0.00																																												
METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)																																												
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input checked="" type="checkbox"/> None		3. ADDITIONAL FEES																																												
<input type="checkbox"/> Deposit Account: Deposit Account Number: 04-0100 Deposit Account Name: Darby & Darby P.C.																																														
The Director is authorized to: (check all that apply)																																														
<input type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments																																														
<input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application																																														
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.																																														
FEE CALCULATION																																														
1. BASIC FILING FEE																																														
<table border="1"><thead><tr><th>Large Entity</th><th>Small Entity</th><th>Fee Description</th><th>Fee Paid</th></tr><tr><th>Fee Code</th><th>Fee (\$)</th><th>Fee Code</th><th>Fee (\$)</th></tr></thead><tbody><tr><td>1001</td><td>770</td><td>2001</td><td>385</td><td>Utility filing fee</td><td></td></tr><tr><td>1002</td><td>340</td><td>2002</td><td>170</td><td>Design filing fee</td><td></td></tr><tr><td>1003</td><td>530</td><td>2003</td><td>265</td><td>Plant filing fee</td><td></td></tr><tr><td>1004</td><td>770</td><td>2004</td><td>385</td><td>Reissue filing fee</td><td></td></tr><tr><td>1005</td><td>160</td><td>2005</td><td>80</td><td>Provisional filing fee</td><td></td></tr><tr><td colspan="4">SUBTOTAL (1) (\$)</td><td>0.00</td></tr></tbody></table>		Large Entity	Small Entity	Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1001	770	2001	385	Utility filing fee		1002	340	2002	170	Design filing fee		1003	530	2003	265	Plant filing fee		1004	770	2004	385	Reissue filing fee		1005	160	2005	80	Provisional filing fee		SUBTOTAL (1) (\$)				0.00		
Large Entity	Small Entity	Fee Description	Fee Paid																																											
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																											
1001	770	2001	385	Utility filing fee																																										
1002	340	2002	170	Design filing fee																																										
1003	530	2003	265	Plant filing fee																																										
1004	770	2004	385	Reissue filing fee																																										
1005	160	2005	80	Provisional filing fee																																										
SUBTOTAL (1) (\$)				0.00																																										
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE																																														
<table border="1"><thead><tr><th>Large Entity</th><th>Small Entity</th><th>Fee Description</th><th>Fee Paid</th></tr><tr><th>Fee Code</th><th>Fee (\$)</th><th>Fee Code</th><th>Fee (\$)</th></tr></thead><tbody><tr><td>1202</td><td>18</td><td>2202</td><td>9</td><td>Claims in excess of 20</td><td></td></tr><tr><td>1201</td><td>86</td><td>2201</td><td>43</td><td>Independent claims in excess of 3</td><td></td></tr><tr><td>1203</td><td>290</td><td>2203</td><td>145</td><td>Multiple dependent claim, if not paid</td><td></td></tr><tr><td>1204</td><td>86</td><td>2204</td><td>43</td><td>** Reissue independent claims over original patent</td><td></td></tr><tr><td>1205</td><td>18</td><td>2205</td><td>9</td><td>** Reissue claims in excess of 20 and over original patent</td><td></td></tr><tr><td colspan="4">SUBTOTAL (2) (\$)</td><td>0.00</td></tr></tbody></table>		Large Entity	Small Entity	Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1202	18	2202	9	Claims in excess of 20		1201	86	2201	43	Independent claims in excess of 3		1203	290	2203	145	Multiple dependent claim, if not paid		1204	86	2204	43	** Reissue independent claims over original patent		1205	18	2205	9	** Reissue claims in excess of 20 and over original patent		SUBTOTAL (2) (\$)				0.00		
Large Entity	Small Entity	Fee Description	Fee Paid																																											
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																											
1202	18	2202	9	Claims in excess of 20																																										
1201	86	2201	43	Independent claims in excess of 3																																										
1203	290	2203	145	Multiple dependent claim, if not paid																																										
1204	86	2204	43	** Reissue independent claims over original patent																																										
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent																																										
SUBTOTAL (2) (\$)				0.00																																										
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$)		0.00																																										
SUBMITTED BY		(Complete if applicable)																																												
Name (Print/Type) S. Peter Ludwig		Registration No. (Attorney/Agent)	25,351																																											
Signature		Telephone	(212) 527-7770																																											
		Date	December 2, 2003																																											
Express Mail Label No. _____ Dated: _____																																														



EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Name (Print)

Signature

Customer No.: 07278

Dkt. No. 04287/100M315-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Arthur Ramazanov and Zakir Ramazanov

Serial No.: 10/660,256

Art Unit:

Confirmation No.:

Filed: September 11, 2003

For: A NOVEL COMPOSITION FOR THE TREATMENT OF OBESITY AND
EFFECTIVE FAT LOSS PROMOTION

December 2, 2003

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

{W:\04287\100M315-US1\00093422.DOC *04287100M315-US1* }

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed: (Check one of the boxes A-D)

- ☒ A. Within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- ☐ B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- ☐ C. after (A) and (B) above, but before the mailing date of a final rejection, a notice of allowance, or any other action that closes prosecution, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- ☐ i. Counsel states that, upon information and belief, each item of information listed herein was either (a) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- ☐ ii. A check for the fee set forth in 1. 17(p), presently believed to be \$180, is enclosed.
- ☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Counsel states that, upon information and belief, each item of information listed herein was either (i) cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS; or (ii) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- ☐ i. A check for the fee set forth in 1.17 (p), presently believed to be \$180, is enclosed.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO-1449) of all patents, publications, or other information submitted for

{W:\04287\100M315-US1\00093422.DOC *04287100M315-US1* }

Docket No. 04287/100M315-US1

consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A and/or B and fill in blanks, if appropriate.)

- ☐ A. Document(s) _____ is (are) deemed substantially cumulative to document(s) _____, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- ☐ B. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

[SERIAL NO. & FILING DATE].

Applicant Identifies these documents by attaching hereto copies of the forms PTO- 892 and PTO- 1449 from the files of the prior application(s) or a fresh PTO- 1449 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

☒ 3. Document No. 46 is not in the English language. In accordance with 1.98(c), Applicant states:

- ☒ An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application is enclosed.
- ☐ A concise explanation of the relevance of document(s) _____ is found in the attached search report (see MPEP § 609 A(3)x).
- ☐ A concise explanation of the relevance of document(s) _____ is set forth as follows: [Insert concise explanation of relevance]
- ☐ A concise explanation of the relevance of document(s) _____ can be found on pages _____ of the specification.
- ☐ A concise explanation of document(s) _____ can be found on the attached sheet.

{W:\04287\100M315-US1\00093422.DOC *04287100M315-US1* }

Docket No. 04287/100M315-US1

[X] 4. No explanation of relevance is necessary for documents in the English language (see MPEP § 609 A(3)).

[] 5. Other information being provided for the examiner's consideration follows:

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of' the item and Applicant reserves the right to prove that the date of publication is in fact different.

CROSS REFERENCE UNDER 37 C.F.R. §1.78 TO RELATED APPLICATIONS

Pursuant to 37 C.F.R. § 1.78, Applicant notes that the above-identified patent application may be related to the following U.S. Patent Applications:

(1) U.S. Patent Application Serial No _____, filed _____.


Early and favorable consideration is earnestly solicited.

Respectfully submitted,



S. Peter Ludwig
Registration No. 25,351
Attorney for Applicant(s)

DARBY & DARBY P.C.
805 Third Avenue
New York, N.Y. 10022
(212) 527-7700



PTO/SB/08a/b (05-03)
Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	US 10/660,256	
			Filing Date	Sept. 11, 2003	
			First Named Inventor	Ramazanov et al.	
			Art Unit		
			Examiner Name		
Sheet	1	of	4	Attorney Docket Number	04287/100M315-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	4,451,465	05-29-1984	White et al.	
	2.	4,772,631	09-20-1988	Holloway et al.	
	3.	4,977,148	12-11-1990	Holloway et al.	
	4.	4,999,377	03-12-1991	Caulkett et al.	
	5.	5,626,849	05-06-1997	Hastings et al.	
	6.	5,783,603	07-21-1998	Majeed et al.	
	7.	5,804,596	09-08-1998	Majeed et al.	
	8.	6,340,482	01-22-2002	Jones	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	9.	Brasaemle et al., (1997) "Post-translational Regulation of Perilipin Expression", <i>The Journal of Biological Chemistry</i> , 272:9378-9387	
	10.	Brasaemle et al. (2000) "Perilipin A Increases Triacylglycerol Storage by Decreasing the Rate of Triacylglycerol Hydrolysis", <i>The Journal of Biological Chemistry</i> , 275:38486-38493	
	11.	Chaudhry and Granneman (1999) "Differential regulation of functional responses by β -adrenergic receptor subtypes in brown adipocytes", <i>Am. J. Physiol.</i> , 277:R147-R153	
	12.	Clifford et al., (1998) "Dephosphorylation of perilipin by protein phosphatases present in rat adipocytes", <i>FEBS Letters</i> , 435:125-129	
	13.	Clifford et al., (2000) "Translocation of Hormone-sensitive Lipase and Perilipin upon Lipolytic Stimulation of Rat Adipocytes", <i>The Journal of Biological Chemistry</i> , 275:5011-5015	

W:\042 87100	Date Considered	
-----------------	--------------------	--



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	US 10/660,256	
			Filing Date	Sept. 11, 2003	
			First Named Inventor	Ramazanov et al.	
			Art Unit		
			Examiner Name		
Sheet	2	of	4	Attorney Docket Number	04287/100M315-US1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	14.	Geodakyan et al., (1992) "High-performance liquid chromatographic method for determination of mangiferin, likviritin and dihydroquercetin in rat plasma and urine", <i>J. of Chromatography</i> , 577:371-375		
	15.	Greenberg et al. (1991) "Perilipin, a Major Hormonally Regulated Adipocyte-specific Phosphoprotein Associated with the Periphery of Lipid Storage Droplets", <i>The Journal of Biological Chemistry</i> , 266:11341-11346		
	16.	Greenberg et al., (1993) "Isolation of cDNAs for perilipins A and B: Sequence and expression of lipid droplet-associated proteins of adipocytes", <i>Proc. Natl. Acad. Sci. USA</i> , 90:12035-12039		
	17.	Han et al., (1998) "Norepinephrine-Augmenting Lipolytic Effectors from <i>Astilbe thunbergii</i> Rhizomes", <i>J. Nat. Prod.</i> , 61:1006-1011		
	18.	Haraguchi et al., (1996) "Inhibition of aldose reductase by dihydroflavonols in <i>Engelhardtia chrysolepis</i> and effects on other enzymes", <i>Experientia</i> , 52: 564-567		
	19.	Haraguchi et al., (1996) "Protection against Oxidative Damage by Dihydroflavonols in <i>Engelhardtia chrysolepis</i> ", <i>Biosci. Biotech. Biochem.</i> 60:945-948		
	20.	Heymsfield et al., (1998) " <i>Garcinia cambogia</i> (Hydroxycitric Acid) as a Potential Antiobesity Agent: A Randomized Controlled Trial", <i>JAMA</i> , 280:1596-1600		
	21.	Holm et al., (2000) "Molecular Mechanisms Regulating Hormone-Sensitive Lipase and Lipolysis", <i>Annu. Rev. Nutr.</i> , 20:365-393		
	22.	Igarashi et al., (1996) "Effect of Astilbin in Tea Processed from Leaves of <i>Engelhardtia chrysolepis</i> on the Serum and Liver Lipid Concentrations and on the Erythrocyte and Liver Antioxidative Enzyme Activities of Rats", <i>Biosci. Biotech. Biochem.</i> , 60:513-515		
	23.	Kellner-Weibel et al., (2001) "Evidence that newly synthesized esterified cholesterol is deposited in existing cytoplasmic lipid inclusions", <i>Journal of Lipid Research</i> , 42:768-777		
	24.	Leonhardt et al., (2002) "Hydroxycitrate Has Long-Term Effects on Feeding Behavior, Body Weight Regain and Metabolism after Body Weight Loss in Male Rats", <i>J. Nutr.</i> , 132:1977-1982		
	25.	Londos et al., (1995) "Perilipin: unique proteins associated with intracellular neutral lipid droplets in adipocytes and steroidogenic cells", <i>Biochem. Society Transactions</i> , 23:611-615		
	26.	Martinez-Botas et al., (2000) "Absence of perilipin results in leanness and reverses obesity in Lep ^{db/db} mice", <i>Nature Genetics</i> , 26:474-479		
	27.	Mauriege et al., (1999) "Regional and gender variations in adipose tissue lipolysis in response to weight loss", <i>J. of Lipid Research</i> , 40:1559-1571		
	28.	Miyase et al., (1996) "Araliasaponins XII-XVIII, triterpene saponins from the roots of <i>Aralia chinensis</i> ", <i>Phytochemistry</i> 42:1123-1130		

(W:042 87:100)	Date Considered	
-------------------	--------------------	--



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	US 10/660,256	
			Filing Date	Sept. 11, 2003	
			First Named Inventor	Ramazanov et al.	
			Art Unit		
			Examiner Name		
Sheet	3	of	4	Attorney Docket Number	04287/100M315-US1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	29.	Miyase et al., (1996) "Araliasaponins I-Xi, triterpene saponins from the roots of <i>Aralia decaisneana</i> ", <i>Phytochemistry</i> , 41:1411-1418		
	30.	Morimoto et al., (1997) "Norepinephrine-induced Lipolysis in Rat Fat Cells from Visceral and Subcutaneous Sites: Role of Hormone-sensitive Lipase and Lipid Droplets", <i>J. of Lipid Research</i> , 38:132-138		
	31.	Morimoto et al., (2000) "Mechanism of the stimulatory action of okadaic acid on lipolysis in rat fat cells", <i>J. of Lipid Research</i> , 41:199-204		
	32.	Morimoto et al., (2000) "Substrate-Dependent Lipolysis Induced by Isoproterenol", <i>Biochem and Biophys Res Comm</i> , 274:631-634		
	33.	Morimoto et al., (2001) "Relationships between lipolysis induced by various lipolytic agents and hormone-sensitive lipase in rat fat cells", <i>J. of Lipid Research</i> , 42:120-127		
	34.	Muls et al., (2001) "The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study", <i>International Journal of Obesity</i> , 25:1713-1721		
	35.	Murphy et al., (2000) "New insights into the mechanisms of lipid-body biogenesis in plants and other organisms", <i>Biochemical Society Transactions</i> , 28:710-711		
	36.	Osterlund T. (2001) "Structure-function relationships of hormone-sensitive lipase", <i>Eur. J. Biochem.</i> , 268:1899-1907		
	37.	Sakai et al., (1994) "Oleanolic acid saponins from root bark of <i>Aralia elata</i> ", <i>Phytochemistry</i> , 35:1319-1324		
	38.	Satoh et al., (1994) "Oleanolic acid saponins from root-bark of <i>Aralia elata</i> ", <i>Phytochemistry</i> , 36:147-152		
	39.	Sedykh et al., (1986) "The Influence of the <i>Aralia Mandshurica</i> Tincture, Aminoron or Their Combination for Memorization of Texts", <i>New Medicinal Preparation from Plants of Siberia and the Far East</i> , p. 132		
	40.	Servetnick et al., (1995) "Perilipins Are Associated with Cholesteryl Ester Droplets in Steroidogenic Adrenal Cortical and Leydig Cells", <i>The Journal of Biological Chem</i> , 270:16970-16973		
	41.	Snow J.M. (1995) " <i>Coleus forskohlii</i> Willd. (Lamiaceae)", <i>The Protocol Journal of Botanical Medicine</i> , pg. 39-42		
	42.	Souquet et al., (2000) "Phenolic Composition of Grape Stems", <i>J. Agric. Food Chem.</i> , 48:1076-1080		
	43.	Souza et al., (1998) "Overexpression of Perilipin A and B Blocks the Ability of Tumor Necrosis Factor α to Increase Lipolysis in 3T3-L1 Adipocytes", <i>The Journal of Biological Chemistry</i> , 273:24665-24669		

{W:\042 87100	Date Considered	
------------------	--------------------	--



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	US 10/660,256	
			Filing Date	Sept. 11, 2003	
			First Named Inventor	Ramazanov et al.	
			Art Unit		
			Examiner Name		
Sheet	4	of	4	Attorney Docket Number	04287/100M315-US1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	44.	Tansey et al., (2001) "Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity", <i>PNAS</i> , 98:6494-6499		
	45.	Theriault et al., (2000) "Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavonoid", <i>Journal of Lipid Research</i> , 41:1969-1979		
	46.	Tiukavkina et al., (1997) "Dihydroquercetin - a new antioxidant and biologically active food additive", <i>Vopr Pitan</i> , 6:12-15		
	47.	Wang et al., (1994) "Chemical analysis of main medicinal species of genus <i>Aralia</i> ", <i>Chung Kuo Chung Yao Tsa Chih</i> , 19:6-8		
	48.	Yamamoto et al., (2000) "Anti-obesity effects of lipase inhibitor CT-II, an extract from edible herbs, <i>Nomame Herba</i> , on rats fed a high-fat diet", <i>International Journal of Obesity</i> , 24:758-764		
	49.	Yoshikawa et al., (1995) "Medicinal foodstuffs. I. Hypoglycemic constituents from a garnish foodstuff "taranome," the young shoot of <i>Aralia elata</i> SEEM: elatosides G, H, I, J, and K", <i>Chem Pharm Bull</i> , 43:1878-1882		
	50.	Yoshikawa et al., (1996) "Bioactive saponins and Glycosides. VI. Elatosides A and B, Potent Inhibitors of Ethanol Absorption, from the Bark of <i>Aralia elata</i> SEEM. (Araliaceae): The Structure-Requirement in Oleanolic Acid Glucuronide-Saponins for the Inhibitory Activity", <i>Chem. Pharm. Bull.</i> , 44:1915-1922		
	51.	Yoshikawa et al., (1996) "Bioactive saponins and glycosides. VII. On the hypoglycemic principles from the root cortex of <i>Aralia elata</i> Seem.: Structure related hypoglycemic activity of oleanolic acid oligoglycoside", <i>Chem Pharm Bull</i> , 44:1923-1927		
	52.	Yu et al., (1994) "Triterpenoid saponins from the roots of <i>Aralia spinifolia</i> ", <i>J Nat Prod</i> , 57:978-982		
	53.	Zeng et al., (1994) "Chemical constituents of <i>Aralia decaisneana</i> Hance", <i>Chung Kuo Chung Yao Tsa Chih</i> , 19:550-551		
	54.	Zweytick et al., (2000) "Intracellular lipid particles of eukaryotic cells", <i>Biochemica et Biophysica Acta</i> , 1469:101-120		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

W:042 87100		Date Considered	
----------------	--	--------------------	--